At present, the third generation EFGR-TKIs, such as Osimertinib or Aumolertinib, significantly improve response rates, progression-free survival (PFS), and overall survival (OS) in lung cancer patients with EGFR mutations [6, 7], but the outcome of partial patients remains extremely poor. The gene discussed is EGFR; the disease is lung cancer.